Alzheimer's disease (AD) is a neurodegenerative disease that is usually accompanied by aging, increasingly being the most common cause of dementia in the elderly. This disorder is characterized by the accumulation of beta amyloid plaques (Aβ) resulting from impaired amyloid precursor protein (APP) metabolism, together with the formation of neurofibrillary tangles and tau protein hyperphosphorylation. The exacerbated production of reactive oxygen species (ROS) triggers the process called oxidative stress, which increases neuronal cell abnormalities, most often followed by apoptosis, leading to cognitive dysfunction and dementia. In this context, the development of new therapies for the AD treatment is necessary. Antioxidants, for instance, are promising species for prevention and treatment because they are capable of disrupting the radical chain reaction, reducing the production of ROS. These species have also proven to be adjunctive to conventional treatments making them more effective. In this sense, several recently published works have focused their attention on oxidative stress and antioxidant species. Therefore, this review seeks to show the most relevant findings of these studies.

Center for Basic and Applied Research Faculty of Informatics and Management University of Hradec Kralove 500 03 Hradec Kralove Czech Republic

Department of Chemistry Federal University of Lavras 37200 000 Lavras Minas Gerais Brazil

Zobrazit více v PubMed

de Castro A.A., Soares F.V., Pereira A.F., Polisel D.A., Caetano M.S., Leal D.H.S., da Cunha E.F.F., Nepovimova E., Kuca K., Ramalho T.C. Non-conventional compounds with potential therapeutic effects against Alzheimer’s disease. Expert Rev. Neurother. 2019;19:375–395. doi: 10.1080/14737175.2019.1608823. PubMed DOI

Gustavsson A., Green C., Jones R.W., Förstl H., Simsek D., de Reydet de Vulpillieres F., Luthman S., Adlard N., Bhattacharyya S., Wimo A. Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer’s disease. Alzheimer’s Dement. 2017;13:312–321. doi: 10.1016/j.jalz.2016.12.005. PubMed DOI

Anand A., Patience A.A., Sharma N., Khurana N. The present and future of pharmacotherapy of Alzheimer’s disease: A comprehensive review. Eur. J. Pharmacol. 2017;815:364–375. doi: 10.1016/j.ejphar.2017.09.043. PubMed DOI

Anand R., Gill K.D., Mahdi A.A. Therapeutics of Alzheimer’s disease: Past, present and future. Neuropharmacology. 2014;76:27–50. doi: 10.1016/j.neuropharm.2013.07.004. PubMed DOI

De Castro A.A., da Cunha E.F.F., Pereira A.F., Soares F.V., Leal D.H.S., Kuca K., Ramalho T.C. Insights into the Drug Repositioning Applied to the Alzheimer’s Disease Treatment and Future Perspectives. Curr. Alzheimer Res. 2018;15:1161–1178. doi: 10.2174/1567205015666180813150703. PubMed DOI

Tarafdar A., Pula G. The Role of NADPH Oxidases and Oxidative Stress in Neurodegenerative Disorders. Int. J. Mol. Sci. 2018;19:3824. doi: 10.3390/ijms19123824. PubMed DOI PMC

Kishida K.T., Klann E. Sources and targets of reactive oxygen species in synaptic plasticity and memory. Antioxid. Redox Signal. 2007;9:233–244. doi: 10.1089/ars.2007.9.233. PubMed DOI PMC

Rego A.C., Oliveira C.R. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: Implications for the pathogenesis of neurodegenerative diseases. Neurochem. Res. 2003;28:1563–1574. doi: 10.1023/A:1025682611389. PubMed DOI

Qiao J., Arthur J.F., Gardiner E.E., Andrews R.K., Zeng L., Xu K. Regulation of platelet activation and thrombus formation by reactive oxygen species. Redox Biol. 2018;14:126–130. doi: 10.1016/j.redox.2017.08.021. PubMed DOI PMC

Finkel T. Signal Transduction by reactive oxygen species. J. Cell Biol. 2011;194:531–549. doi: 10.1083/jcb.201102095. PubMed DOI PMC

Cheignon C., Tomas M., Bonnefont- Rousselot D., Faller P., Hureau C., Collin F. Oxidative Stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol. 2018;14:450–464. doi: 10.1016/j.redox.2017.10.014. PubMed DOI PMC

Wang X., Wang W., Li L., Perry G., Lee H., Zhu X. Oxidative Stress and mitochondrial dysfunction in alzheimer disease. Biochim. et Biophys. Acta. 2014;1842:1240–1247. doi: 10.1016/j.bbadis.2013.10.015. PubMed DOI PMC

Tonnies E., Trushina E. Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s disease. J. Alzheimer Diases. 2017;57:1105–1121. doi: 10.3233/JAD-161088. PubMed DOI PMC

Collin F., Cheignon C., Hureau C. Oxidative Stress as a biomarker for alzheimer disease. Biomarker Med. 2018;12:201–203. doi: 10.2217/bmm-2017-0456. PubMed DOI

Wojtunik- Kulesza K., Oniszczuck A., Oniszczuck T., Waksmundzka-Hajnos M. The influence of common free radicals and antoxidants on development of alzheimer’s disease. Biomed. Pharmacoth. 2016;78:39–49. doi: 10.1016/j.biopha.2015.12.024. PubMed DOI

Kim G.H., Kim J.E., Rhie S.J., Yon S. The role of oxidative stress in neurodegenerative disease. Exp. Neurobiol. 2015;24:325–340. doi: 10.5607/en.2015.24.4.325. PubMed DOI PMC

Hung C.H.L., Cheng S.S.Y., Cheung Y.T., Wuwongse S., Zhang N.Q., Ho Y.S., Lee S.M.Y., Chang R.C.C. A reciprocal relationship between reactive oxygen species and mitochondrial dynamics in neurodegeneration. Redox Biol. 2018;14:7–19. doi: 10.1016/j.redox.2017.08.010. PubMed DOI PMC

Jiang T., Sun Q., Chen S. Oxidative Stress: A major pathogenises and potential therapeutics target of antioxidative agents in Parkinson’s disease and Alzheimer disease. Prog. Nurobiol. 2016;147:1–19. doi: 10.1016/j.pneurobio.2016.07.005. PubMed DOI

Kamat P.K., Kalani A., Rai S., Swarnkar S., Tota S., Nath C., Tyagi N. Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of alzheimer’s disease: Understanding the therapeutics strategies. Mol. Neurobiol. 2016;53:648–661. doi: 10.1007/s12035-014-9053-6. PubMed DOI PMC

Dutordoir R.M., Bates D.A.A. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim. et. Biophys. Acta. 2016;1863:2977–2992. doi: 10.1016/j.bbamcr.2016.09.012. PubMed DOI

Karran E., Mercken M., De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 2011;10:698–712. doi: 10.1038/nrd3505. PubMed DOI

Jones E.L., Hanney M., Francis P.T., Ballard C.G. Amyloid beta concentrations in older people with Down syndrome and dementia. Neurosci. Lett. 2009;451:162–164. doi: 10.1016/j.neulet.2008.12.030. PubMed DOI

Broadstock M., Ballard C., Corbett A. Latest treatment options for Alzheimer’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. Expert Opin. Pharmacother. 2014;15:1797–1810. doi: 10.1517/14656566.2014.936848. PubMed DOI

Saez-Orellana F., Godoy P.A., Bastidas C.Y., Silva-Grecchi T., Guzman L., Aguayo L.G., Fuentealba J. ATP leakage induces P2XR activation and contributes to acute synaptic excitotoxicity induced by soluble oligomers of beta-amyloid peptide in hippocampal neurons. Neuropharmacology. 2016;100:116–123. doi: 10.1016/j.neuropharm.2015.04.005. PubMed DOI

Godyn J., Jonczyk J., Panek D., Malawska B. Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol. Rep. 2016;68:127–138. doi: 10.1016/j.pharep.2015.07.006. PubMed DOI

Serrano-Pozo A., Frosch M.P., Masliah E., Hyman B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011;1:a006189. doi: 10.1101/cshperspect.a006189. PubMed DOI PMC

Golde T.E. The pathogenesis of Alzheimer’s disease and the role of Abeta42. CNS Spectr. 2007;12:4–6. doi: 10.1017/S1092852900025876. PubMed DOI

Schenk D., Basi G.S., Pangalos M.N. Treatment strategies targeting amyloid beta-protein. Cold Spring Harb. Perspect. Med. 2012;2:a006387. doi: 10.1101/cshperspect.a006387. PubMed DOI PMC

Xiao Y., Ma B., McElheny D., Parthasarathy S., Long F., Hoshi M., Nussinov R., Ishii Y. Abeta(1–42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer’s disease. Nat. Struct. Mol. Biol. 2015;22:499–505. doi: 10.1038/nsmb.2991. PubMed DOI PMC

Hardy J. The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal. J. Neurochem. 2009;110:1129–1134. doi: 10.1111/j.1471-4159.2009.06181.x. PubMed DOI

Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science. 2002;297:353–356. doi: 10.1126/science.1072994. PubMed DOI

Hardy J.A., Higgins G.A. Alzheimer’s disease: The amyloid cascade hypothesis. Science. 1992;256:184–185. doi: 10.1126/science.1566067. PubMed DOI

Glenner G.G., Wong C.W. Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984;120:885–890. doi: 10.1016/S0006-291X(84)80190-4. PubMed DOI

Thinakaran G., Koo E.H. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 2008;283:29615–29619. doi: 10.1074/jbc.R800019200. PubMed DOI PMC

Sales T.A., Prandi I.G., de Castro A.A., Leal D.H.S., da Cunha E.F.F., Kuca K., Ramalho T.C. Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments. Int. J. Mol. Sci. 2019;20:1829. doi: 10.3390/ijms20081829. PubMed DOI PMC

Grill J.D., Cummings J.L. Current therapeutic targets for the treatment of Alzheimer’s disease. Expert Rev. Neurother. 2010;10:711–728. doi: 10.1586/ern.10.29. PubMed DOI PMC

Bachurin S.O., Bovina E.V., Ustyugov A.A. Drugs in Clinical Trials for Alzheimer’s Disease: The Major Trends. Med. Res. Rev. 2017;37:1186–1225. doi: 10.1002/med.21434. PubMed DOI

Levey A.I., Kitt C.A., Simonds W.F., Price D.L., Brann M.R. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 1991;11:3218–3226. doi: 10.1523/JNEUROSCI.11-10-03218.1991. PubMed DOI PMC

Holtzman D.M., Morris J.C., Goate A.M. Alzheimer’s disease: The challenge of the second century. Sci. Transl. Med. 2011;3:77. doi: 10.1126/scitranslmed.3002369. PubMed DOI PMC

Nisbet R.M., Polanco J.-C., Ittner L.M., Gotz J. Tau aggregation and its interplay with amyloid-beta. Acta. Neuropathol. 2015;129:207–220. doi: 10.1007/s00401-014-1371-2. PubMed DOI PMC

Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. Sci. 1991;12:383–388. doi: 10.1016/0165-6147(91)90609-V. PubMed DOI

Garcia M.L., Cleveland D.W. Going new places using an old MAP: Tau, microtubules and human neurodegenerative disease. Curr. Opin. Cell Biol. 2001;13:41–48. doi: 10.1016/S0955-0674(00)00172-1. PubMed DOI

Wischik C.M., Harrington C.R., Storey J.M.D. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem. Pharmacol. 2014;88:529–539. doi: 10.1016/j.bcp.2013.12.008. PubMed DOI

Lee V.M.-Y., Trojanowski J.Q. The disordered neuronal cytoskeleton in Alzheimer’s disease. Curr. Opin. Neurobiol. 1992;2:653–656. doi: 10.1016/0959-4388(92)90034-I. PubMed DOI

Clark C.M., Xie S., Chittams J., Ewbank D., Peskind E., Galasko D., Morris J.C., McKeel D.W.J., Farlow M., Weitlauf S.L., et al. Cerebrospinal fluid tau and beta-amyloid: How well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch. Neurol. 2003;60:1696–1702. doi: 10.1001/archneur.60.12.1696. PubMed DOI

Steinhilb M.L., Dias-Santagata D., Fulga T.A., Felch D.L., Feany M.B. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol. Biol. Cell. 2007;18:5060–5068. doi: 10.1091/mbc.e07-04-0327. PubMed DOI PMC

Schneider A., Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics. 2008;5:443–457. doi: 10.1016/j.nurt.2008.05.006. PubMed DOI PMC

Illenberger S., Zheng-Fischhofer Q., Preuss U., Stamer K., Baumann K., Trinczek B., Biernat J., Godemann R., Mandelkow E.M., Mandelkow E. The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: Implications for Alzheimer’s disease. Mol. Biol. Cell. 1998;9:1495–1512. doi: 10.1091/mbc.9.6.1495. PubMed DOI PMC

Gong C.-X., Liu F., Grundke-Iqbal I., Iqbal K. Post-translational modifications of tau protein in Alzheimer’s disease. J. Neural Transm. 2005;112:813–838. doi: 10.1007/s00702-004-0221-0. PubMed DOI

Iqbal K., Liu F., Gong C.-X. Tau and neurodegenerative disease: The story so far. Nat. Rev. Neurol. 2016;12:15–27. doi: 10.1038/nrneurol.2015.225. PubMed DOI

Wu X.-L., Pina-Crespo J., Zhang Y.-W., Chen X.-C., Xu H.-X. Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer’s Disease. Chin. Med. J. (Engl.) 2017;130:2978–2990. doi: 10.4103/0366-6999.220313. PubMed DOI PMC

Congdon E.E., Sigurdsson E.M. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 2018 doi: 10.1038/s41582-018-0013-z. PubMed DOI PMC

Davies P., Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet (London, England) 1976;2:1403. doi: 10.1016/S0140-6736(76)91936-X. PubMed DOI

Kar S., Issa A.M., Seto D., Auld D.S., Collier B., Quirion R. Amyloid beta-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J. Neurochem. 1998;70:2179–2187. doi: 10.1046/j.1471-4159.1998.70052179.x. PubMed DOI

Auld D.S., Kar S., Quirion R. Beta-amyloid peptides as direct cholinergic neuromodulators: A missing link? Trends Neurosci. 1998;21:43–49. doi: 10.1016/S0166-2236(97)01144-2. PubMed DOI

Nordberg A., Alafuzoff I., Winblad B. Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia. J. Neurosci. Res. 1992;31:103–111. doi: 10.1002/jnr.490310115. PubMed DOI

Barage S.H., Sonawane K.D. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer’s disease. Neuropeptides. 2015;52:1–18. doi: 10.1016/j.npep.2015.06.008. PubMed DOI

Franklin M.C., Rudolph M.J., Ginter C., Cassidy M.S., Cheung J. Structures of paraoxon-inhibited human acetylcholinesterase reveal perturbations of the acyl loop and the dimer interface. Proteins. 2016;84:1246–1256. doi: 10.1002/prot.25073. PubMed DOI

Lleo A., Greenberg S.M., Growdon J.H. Current pharmacotherapy for Alzheimer’s disease. Ann. Rev. Med. 2006;57:513–533. doi: 10.1146/annurev.med.57.121304.131442. PubMed DOI

Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 2011;7:137–152. doi: 10.1038/nrneurol.2011.2. PubMed DOI PMC

Contestabile A. The history of the cholinergic hypothesis. Behav. Brain Res. 2011;221:334–340. doi: 10.1016/j.bbr.2009.12.044. PubMed DOI

Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch. Neurol. 2003;60:1119–1122. doi: 10.1001/archneur.60.8.1119. PubMed DOI

Rogers S.L., Farlow M.R., Doody R.S., Mohs R., Friedhoff L.T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology. 1998;50:136–145. doi: 10.1212/WNL.50.1.136. PubMed DOI

Corey-Bloom J., Anand R., Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int. J. Geriatr. Psyopharmacol. 1998;1:55–65.

Tariot P.N., Solomon P.R., Morris J.C., Kershaw P., Lilienfeld S., Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54:2269–2276. doi: 10.1212/WNL.54.12.2269. PubMed DOI

Cummings J.L. Cholinesterase inhibitors: A new class of psychotropic compounds. Am. J. Psychiatry. 2000;157:4–15. doi: 10.1176/ajp.157.1.4. PubMed DOI

Ryan J., Scali J., Carriere I., Ritchie K., Ancelin M.-L. Hormonal treatment, mild cognitive impairment and Alzheimer’s disease. Int. Psychogeriatr. 2008;20:47–56. doi: 10.1017/S1041610207006485. PubMed DOI PMC

Giacobini E. Cholinesterase inhibitors stabilize Alzheimer’s disease. Ann. N. Y. Acad. Sci. 2000;920:321–327. doi: 10.1111/j.1749-6632.2000.tb06942.x. PubMed DOI

Machado L.P., Kohaygawa A., Saito M.E., da Silveira V.F., Yonezawa L.A. Lesão Oxidativa eritrocitária e mecanismos antioxidantes. Rev. Ciências Agroveterinárias. 2009;8:84–94.

Barreiros A.L.B.S., David J.M., David J.P. Estresse oxidativo: relaçÃ\poundso entre geraçÃ\poundso de espÃ\copyrightcies reativas e defesa do organismo. QuÃ\-mica Nov. 2006;29:113–123.

de Oliveira M.C., Schoffen J.P.F. Oxidative stress action in cellular aging. Braz. Arch. Biol. Technol. 2010;53:1333–1342. doi: 10.1590/S1516-89132010000600009. DOI

Celi P. The role of oxidative stress in small ruminants’ health and production. Rev. Bras. Zootec. 2010;39:348–363. doi: 10.1590/S1516-35982010001300038. DOI

Ferreira A.L.A., Matsubara L.S. Radicais livres: Conceitos, doenÃ\Sas relacionadas, sistema de defesa e estresse oxidativo. Rev. da Assoc. MÃ\copyrightdica Bras. 1997;43:61–68. doi: 10.1590/S0104-42301997000100014. PubMed DOI

Halliwell B., Clement M.V., Long L.H. Hydrogen peroxide in the human body. FEBS Lett. 2000;486:10–13. doi: 10.1016/S0014-5793(00)02197-9. PubMed DOI

Babior B.M. Superoxide: A two-edged sword. Braz. J. Med. Biol. Res. 1997;30:141–155. doi: 10.1590/S0100-879X1997000200001. PubMed DOI

Vina J., Lloret A., Orti R., Alonso D. Molecular bases of the treatment of Alzheimer’s disease with antioxidants: Prevention of oxidative stress. Mol. Aspects Med. 2004;25:117–123. doi: 10.1016/j.mam.2004.02.013. PubMed DOI

Aliev G., Obrenovich M.E., Tabrez S., Jabir N.R., Reddy V.P., Li Y., Burnstock G., Cacabelos R., Kamal M.A. Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA overproliferation and deletion. Oxid. Med. Cell. Longev. 2013;2013:962984. doi: 10.1155/2013/962984. PubMed DOI PMC

Blennow K., de Leon M.J., Zetterberg H. Alzheimer’s disease. Lancet (London, England) 2006;368:387–403. doi: 10.1016/S0140-6736(06)69113-7. PubMed DOI

Hauptmann S., Keil U., Scherping I., Bonert A., Eckert A., Muller W.E. Mitochondrial dysfunction in sporadic and genetic Alzheimer’s disease. Exp. Gerontol. 2006;41:668–673. doi: 10.1016/j.exger.2006.03.012. PubMed DOI

Ricciarelli R., Argellati F., Pronzato M.A., Domenicotti C. Vitamin E and neurodegenerative diseases. Mol. Aspects Med. 2007;28:591–606. doi: 10.1016/j.mam.2007.01.004. PubMed DOI

Bianchi M.d.L.P., Antunes L.M.G. Radicais livres e os principais antioxidantes da dieta. Rev. Nutr. 1999;12:123–130. doi: 10.1590/S1415-52731999000200001. DOI

Bhatti A.B., Usman M., Ali F., Satti S.A. Vitamin supplementation as an ajuvant treatment for Alzheimer disease. J. Clin. Diagn. Res. 2016;10:7–11. PubMed PMC

Ono K., Yamada M. Vitamin A and Alzheimer’s disease. Geriatrics GerontolIntl. 2012;12:180–188. doi: 10.1111/j.1447-0594.2011.00786.x. PubMed DOI

Gröber U., Kisters K., Schmidt J. Neuroenhancement with vitamin B12-Underestimated neurological significance. Nutrients. 2013;5:5031–5045. PubMed PMC

Presse N., Belleville S., Gaudreau P., Greenwood C.E., Kergoat M.J., Morais J.A. Vitamin K status and cognitive function in healthy older adults. Neurobiol. Aging. 2013;34:2777–2783. doi: 10.1016/j.neurobiolaging.2013.05.031. PubMed DOI

Barbosa K.B.F., Costa N.M.B., Alfenas R.d.C.G., De Paula S.O., Minim V.P.R., Bressan J. Estresse oxidativo: Conceito, implicaçÃ\mues e fatores modulatÃ\textthreesuperiorrios. Rev. Nutr. 2010;23:629–643. doi: 10.1590/S1415-52732010000400013. DOI

Jordao A., Chiarello P.G., Meirelles Bernardes M.S., Vannucchi H., Paulo S. Peroxidação lipídica e etanol: Papel da glutationa reduzida e da vitamina E. Medicina (Ribeirao Preto. Online) 1998;31

Scarmeas N., Luchsinger J.A., Schupf N., Brickman A.M., Cosentino S., Tang M.X., Stern Y. Physical activity, diet, and risk of Alzheimer disease. JAMA. 2009;302:627–637. doi: 10.1001/jama.2009.1144. PubMed DOI PMC

Knopman D.S. Mediterranean diet and late-life cognitive impairment: A taste of benefit. JAMA. 2009;302:686–687. doi: 10.1001/jama.2009.1149. PubMed DOI PMC

Cardoso B.R., Cozzolino S.M.F. Oxidative stress in Alzheimer’s disease: The role of vitamins C and E. Nutr.—Rev. da Soc. Bras. Aliment. e Nutr. 2009;34:249–259.

Manoharan S., Guillemin G.J., Abiramasundari R.S., Essa M.M., Akabar M., Akabar M.D. The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease: A Mini Review. Oxid. Med. Cell. Longev. 2016:1–15. doi: 10.1155/2016/8590578. PubMed DOI PMC

Hay E., Lucariello A., Contieri M., Esposito T., Luca A., Guerra G., Perna A. Therapeutic effects of turmeric in several diseases: An overview. Chem.-Biol. Interact. 2019:310. doi: 10.1016/j.cbi.2019.108729. PubMed DOI

Santos A.M., Lopes T., Oleastro M., Gato I.V., Floch P., Benejat L., Chaves P., Pereira T., Seixas E., Machado J., et al. Curcumin inhibits gastric inflammation induced by Helicobacter pylori infection in a mouse model. Nutrients. 2015;7:306–320. doi: 10.3390/nu7010306. PubMed DOI PMC

Huang X., Moir R.D., Tanzi R.E., Bush A.I., Rogers J.T. Redox-active metals, oxidative stress, and Alzheimer’s disease pathology. Ann. N. Y. Acad. Sci. 2004;1012:153–163. doi: 10.1196/annals.1306.012. PubMed DOI

Jeynes B., Provias J. Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Curr. Alzheimer Res. 2008;5:432–437. doi: 10.2174/156720508785908937. PubMed DOI

Huang W.-J., Zhang X., Chen W.-W. Role of oxidative stress in Alzheimer’s disease. Biomed. Rep. 2016;4:519–522. doi: 10.3892/br.2016.630. PubMed DOI PMC

Chauhan V., Chauhan A. Oxidative stress in Alzheimer’s disease. Pathophysiol. Off. J. Int. Soc. Pathophysiol. 2006;13:195–208. doi: 10.1016/j.pathophys.2006.05.004. PubMed DOI

Peters F., Salihoglu H., Rodrigues E., Herzog E., Blume T., Filser S., Dorostkar M., Shimshek D.R., Brose N., Neumann U., et al. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology. Acta Neuropathol. 2018;135:695–710. doi: 10.1007/s00401-017-1804-9. PubMed DOI PMC

Golde T.E., Koo E.H., Felsenstein K.M., Osborne B.A., Miele L. γ-Secretase inhibitors and modulators. Biochim. Biophys. Acta. 2013;1828:2898–2907. doi: 10.1016/j.bbamem.2013.06.005. PubMed DOI PMC

Holzer M., Schade N., Opitz A., Hilbrich I., Stieler J., Vogel T., Neukel V., Oberstadt M., Totzke F., Schächtele C., et al. Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay. Molecules. 2018;23:2335. doi: 10.3390/molecules23092335. PubMed DOI PMC

Giacomini C., Koo C.-Y., Yankova N., Tavares I.A., Wray S., Noble W., Hanger D.P., Morris J.D.H. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies. Acta Neuropathol. Commun. 2018;6:37. doi: 10.1186/s40478-018-0539-8. PubMed DOI PMC

Yadikar H., Torres I., Aiello G., Kurup M., Yang Z., Lin F., Kobeissy F., Yost R., Wang K.K. Screening of Tau Protein Kinase Inhibitors in a Tauopathy-relevant cell-based model of Tau Hyperphosphorylation and Oligomerization. bioRxiv. 2019:821389. PubMed PMC

Simunkova M., Alwasel S.H., Alhazza I.M., Jomova K., Kollar V., Rusko M., Valko M. Management of oxidative stress and other pathologies in Alzheimer’s disease. Arch. Toxicol. 2019;93:2491–2513. doi: 10.1007/s00204-019-02538-y. PubMed DOI

Giacoppo J.O.S., França T.C.C., Kuča K., Da Cunha E.F.F., Abagyan R., Mancini D.T., Ramalho T.C. Molecular modeling and in vitro reactivation study between the oxime BI-6 and acetylcholinesterase inhibited by different nerve agents. J. Biomol. Struct. Dyn. 2015;33:2048–2058. doi: 10.1080/07391102.2014.989408. PubMed DOI

Pereira A.F., de Castro A.A., Soares F.V., Soares Leal D.H., da Cunha E.F.F., Mancini D.T., Ramalho T.C. Development of technologies applied to the biodegradation of warfare nerve agents: Theoretical evidence for asymmetric homogeneous catalysis. Chem. Biol. Interact. 2019;308:323–331. doi: 10.1016/j.cbi.2019.06.007. PubMed DOI

Polisel D.A., de Castro A.A., Mancini D.T., da Cunha E.F.F., França T.C.C., Ramalho T.C., Kuca K. Slight difference in the isomeric oximes K206 and K203 makes huge difference for the reactivation of organophosphorus-inhibited AChE: Theoretical and experimental aspects. Chem. Biol. Interact. 2019;309:108671. doi: 10.1016/j.cbi.2019.05.037. PubMed DOI

Prandi I.G., Ramalho T.C., França T.C.C. Esterase 2 as a fluorescent biosensor for the detection of organophosphorus compounds: Docking and electronic insights from molecular dynamics. Mol. Simul. 2019;45:1432–1436. doi: 10.1080/08927022.2019.1648808. DOI

Da Silva J.A.V., Nepovimova E., Ramalho T.C., Kuca K., Celmar Costa França T. Molecular modeling studies on the interactions of 7-methoxytacrine-4-pyridinealdoxime, 4-PA, 2-PAM, and obidoxime with VX-inhibited human acetylcholinesterase: A near attack conformation approach. J. Enzyme Inhib. Med. Chem. 2019;34:1018–1029. doi: 10.1080/14756366.2019.1609953. PubMed DOI PMC

Soares F.V., de Castro A.A., Pereira A.F., Leal D.H.S., Mancini D.T., Krejcar O., Ramalho T.C., da Cunha E.F.F., Kuca K. Theoretical Studies Applied to the Evaluation of the DFPase Bioremediation Potential against Chemical Warfare Agents Intoxication. Int. J. Mol. Sci. 2018;19:1257. doi: 10.3390/ijms19041257. PubMed DOI PMC